Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 7,579 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Clear all
Completed Phase 2 Interventional Results available

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

NCT01349101
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
Radiation · Drug · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 3 Interventional

Treatment of Adults With Growth Hormone Deficiency

NCT00294619
View directory record Official record
Conditions
Pituitary Disorders, Adult Growth Hormone Deficiency
Interventions
growth hormone
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
23 Years to 70 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

NCT02918292
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide, Total Body Irradiation (TBI), Haplo HSCT, Tacrolimus, Mycophenolate mofetil (MMF), G-CSF
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Oakland, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ulixertinib, Ruxolitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

NCT03734601
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia, B-cell Lymphoma, T-cell Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus, Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 21, 2026, 5:35 AM EDT
Enrolling by invitation No phase listed Observational

Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

NCT06000319
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Natural Matrix Protein (NMP) Fibers, Lumbar interbody fusion, Cervical interbody fusion
Biological · Procedure
Lead sponsor
Induce Biologics USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jasper, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 21, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Interventions
LY3410738, Venetoclax, Azacitidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

NCT03287245
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Idasanutlin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

NCT00352001
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
azacitidine, lenalidomide
Drug
Lead sponsor
Mikkael Sekeres MD
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional

Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

NCT01050439
View directory record Official record
Conditions
Leukemia, Lymphoma, Bone Marrow Failure Syndromes, Immunodeficiencies, Histiocytosis
Interventions
UDAlloSCT, Therapy
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PKC412 and 5-Azacytidine

NCT01202877
View directory record Official record
Conditions
Leukemia
Interventions
5-azacytidine, PKC412
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 21, 2026, 5:35 AM EDT
Active, not recruiting No phase listed Observational

The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis

NCT02389075
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Ankylosing Spondylitis (AS)
Interventions
Pinch biopsies, Flexible sigmoidoscopy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 21, 2026, 5:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Vitamin D Retrospective Study and Role With Disease

NCT01798030
View directory record Official record
Conditions
Vitamin D Status, Glucose Tolerance, Blood Pressure, Bone Mineral Density, Hyperlipidemia
Interventions
Vitamin D
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
45 Years to 85 Years
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional Results available

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

NCT01034592
View directory record Official record
Conditions
Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Lenalidomide
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 21, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

NCT03093909
View directory record Official record
Conditions
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasm of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract, Melanoma and Other Malignant Neoplasms of Skin
Interventions
Gemcitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Results available

Transition From Alendronate to Romosozumab (AMG 785)

NCT01588509
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 21, 2026, 5:35 AM EDT
Not listed Phase 1Phase 2 Interventional

CEP-701 (Lestaurtinib) in Myelofibrosis

NCT00668421
View directory record Official record
Conditions
Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Interventions
CEP-701 (Lestaurtinib)
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
7
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

NCT01430299
View directory record Official record
Conditions
Stenosis, Spondylosis, Degenerative Changes
Interventions
Demineralized Bone Matrix, rh-BMP2
Device
Lead sponsor
SeaSpine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 21, 2026, 5:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

NCT00235599
View directory record Official record
Conditions
Short Stature, Growth Hormone Deficiency
Interventions
IGFBP-3 Stimulation Test
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 21, 2026, 5:35 AM EDT
Not listed No phase listed Observational

Samples From Leukemia Patients and Their Donors to Identify Specific Antigens

NCT02667093
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
PersImmune, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
La Jolla, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 5:35 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Immediate vs Delayed Placement of Straumann BLX Implants in Molar Extraction Sockets

NCT04327284
View directory record Official record
Conditions
Immediate Placement of Straumann BLX Implants in Molar Extraction Sockets
Interventions
Immediate placement non-occlusal loading molar implant (Straumann BLX 6.5mm), Delayed placement non-occlusal loading molar implant (Straumann BLX 5.0mm)
Device
Lead sponsor
Ahmad Kutkut
Other
Eligibility
22 Years to 78 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 21, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

NCT00248547
View directory record Official record
Conditions
Cancer
Interventions
aprepitant, dexamethasone, ondansetron, placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 5:35 AM EDT
Terminated No phase listed Observational

Localized Alveolar Ridge Augmentation With Space Maintenance Devices

NCT00991432
View directory record Official record
Conditions
Alveolar Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Greenwood Village, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 21, 2026, 5:35 AM EDT
Completed No phase listed Observational

Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)

NCT00948532
View directory record Official record
Conditions
Degenerative Disc Disease, Back Pain
Interventions
biologic, Osteocel Plus
Biological
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 80 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
13
States / cities
La Jolla, California • Hollywood, Florida • Miami Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 5:35 AM EDT